These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 32445941)
21. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Hashimoto S; Koike T; Tatewaki W; Seki Y; Sato N; Azegami T; Tsukada N; Takahashi H; Kimura H; Ueno M Leukemia; 1994 Jul; 8(7):1113-5. PubMed ID: 8035603 [TBL] [Abstract][Full Text] [Related]
22. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Kawano N; Kuriyama T; Yoshida S; Yamashita K; Ochiai H; Nakazaki S; Tasaki A; Ueda A Intern Med; 2013; 52(1):55-62. PubMed ID: 23291674 [TBL] [Abstract][Full Text] [Related]
23. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule. Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658 [TBL] [Abstract][Full Text] [Related]
24. Advances in the management of coagulopathy in acute promyelocytic leukemia. Sanz MA; Montesinos P Thromb Res; 2020 Jul; 191 Suppl 1():S63-S67. PubMed ID: 32736781 [TBL] [Abstract][Full Text] [Related]
25. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Yanada M; Matsushita T; Asou N; Kishimoto Y; Tsuzuki M; Maeda Y; Horikawa K; Okada M; Ohtake S; Yagasaki F; Matsumoto T; Kimura Y; Shinagawa K; Iwanaga M; Miyazaki Y; Ohno R; Naoe T Eur J Haematol; 2007 Mar; 78(3):213-9. PubMed ID: 17241371 [TBL] [Abstract][Full Text] [Related]
26. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592 [TBL] [Abstract][Full Text] [Related]
27. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment. Raanani P; Segal E; Levi I; Bercowicz M; Berkenstat H; Avigdor A; Perel A; Ben-Bassat I Leuk Lymphoma; 2000 May; 37(5-6):605-10. PubMed ID: 11042521 [TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Testa U; Lo-Coco F Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716 [TBL] [Abstract][Full Text] [Related]
29. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? Mantha S; Tallman MS; Soff GA Curr Opin Hematol; 2016 Mar; 23(2):121-6. PubMed ID: 26760586 [TBL] [Abstract][Full Text] [Related]
32. New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases. Li H; Han C; Li K; Li J; Wang Y; Xue F Cancer Biol Ther; 2019; 20(4):397-401. PubMed ID: 30453810 [TBL] [Abstract][Full Text] [Related]
33. [Complete remission of acute promyelocytic leukemia accompanied by DIC in an elderly patient treated with all-trans retinoic acid]. Handa H; Jinbo T; Okamoto K; Hirabayashi H; Miyawaki S Nihon Ronen Igakkai Zasshi; 1993 Feb; 30(2):146-9. PubMed ID: 8483289 [TBL] [Abstract][Full Text] [Related]
34. Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia. Xiao M; Zhou P; Liu Y; Wei S; Li D; Li W; Niu X; Niu J; Zhang Y; Cao W; Liu B; Wang X; Bai Y; Sun K Thromb Res; 2022 Feb; 210():33-41. PubMed ID: 34998209 [TBL] [Abstract][Full Text] [Related]
35. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience]. Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms and management of coagulopathy in acute promyelocytic leukemia. David S; Mathews V Thromb Res; 2018 Apr; 164 Suppl 1():S82-S88. PubMed ID: 29703489 [TBL] [Abstract][Full Text] [Related]
37. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Koseki M; Asada N; Uryu H; Takeuchi M; Asakura H; Matsue K Int J Hematol; 2007 Dec; 86(5):403-6. PubMed ID: 18192107 [TBL] [Abstract][Full Text] [Related]
39. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia]. Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674 [TBL] [Abstract][Full Text] [Related]
40. [Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation]. Yang H; Zhu CY; Wang QS; Niu JH; Zhang Q; Zhu HY; Yao ZL; Xu YY; Jing Y; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):315-22. PubMed ID: 24762998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]